<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778659</url>
  </required_header>
  <id_info>
    <org_study_id>CHAM</org_study_id>
    <nct_id>NCT02778659</nct_id>
  </id_info>
  <brief_title>Hypnotic Intake and Motor and Cognitive Performances at High Altitude</brief_title>
  <acronym>CHAM</acronym>
  <official_title>The Effect of Acute Hypnotic Intake Before a Night at High Altitude on Cognitive and Motor Performances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Expertise sur l’Altitude EXALT</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d’Expertise sur l’Altitude EXALT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effect of acute hypnotic intake (Zolpidem) on sleep,
      cognitive and motor performances and on acute mountain sickness symptoms at high altitude.
      Healthy subjects will be evaluated on 4 occasions (twice at sea level and twice at high
      altitude), after hypnotic or placebo intake. Following an early wake-up (01:00), symptoms,
      cognitive and motor performances will be assessed to determine potential residual effects of
      Zolpidem within such conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive performance assessed using Simon cognitive test</measure>
    <time_frame>4 hours after drug/placebo intake</time_frame>
    <description>Simon cognitive test</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Physiology</condition>
  <arm_group>
    <arm_group_label>Zolpidem Normoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute zolpidem intake at sea level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Normoxia</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Acute placebo intake at sea level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem Hypoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute zolpidem intake at high altitude</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Hypoxia</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Acute placebo intake at high altitude</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.</description>
    <arm_group_label>Zolpidem Normoxia</arm_group_label>
    <arm_group_label>Zolpidem Hypoxia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.</description>
    <arm_group_label>Placebo Normoxia</arm_group_label>
    <arm_group_label>Placebo Hypoxia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No sojourn above 2500 m during the past 2 months

          -  Coffee intake &lt; 3 cups per day

          -  Non-smoker

        Exclusion Criteria:

          -  Respiratory, cardiovascular, metabolic or neuromuscular diseases

          -  Psychiatric disorders

          -  Use of hypnotics within the past year

          -  Dependence syndrome (alcool, drugs, etc)

          -  Severe insomnia or somnolence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Bouzat, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <state>Rhone Alpes</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

